Agios Pharmaceuticals (AGIO) Stock Price, Quote & News

Company Profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pedi...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 649 8600

Website: www.agios.com

Address:

88 Sidney Street, Cambridge, United States

Merlintrader Sep. 12 at 5:13 PM

$AGIO $RARE $SRRK $SMMT — Top Ten Biotech Stocks Right Now: the names leading the current Merlintrader ranking https://www.merlintrader.com/top-ten-biotech-stocks-right-now/

0 · Reply

stu4 Sep. 9 at 1:03 PM

$AGIO any truth !!! They lied about liver reaction until they sold their qtrly given options to sell. They lied more recently of the trial they ended. They knew in phase 1/b , CMO Sara G , sells stock like an addiction to drugs ,and she sees and creates the trials . Her experience is so pathetic, so not genius ! Bowden was the secret , Schenkien was the first liar ! Street punished him, and still do, because he brought in a crony from Celgene , Fouse . Maraganore never asked him ( Schenkien) over to his new entity, City Therapeutics, yet, sat on his board at AGIOS for years . Guess disgust was the reason. Others from ALNY are on the board . Tells the public , the brains of AGIOS aren’t what is at ALNY . Get enough ??? @eeyore1 , Mike !!

1 · Reply

eeyore1 Sep. 7 at 3:15 AM

$AGIO What kind of truth you are looking for?

0 · Reply

stu4 Sep. 4 at 1:26 AM

$AGIO can anyone there tell the truth They are all liars …colons of Trump

0 · Reply

TNNStockAnalysisNews Sep. 4 at 1:00 AM

Stocks to Watch Tomorrow, Sep 4, 2026: $TE — Closed Near $4.51, Pivoting From Solar Into AI Data Centers $ARTV — Trading Near $9.78, a 300%+ Analyst Target Gap $SHIP — A Dry Bulk Shipper Near $18, Up 24.8% in Two Weeks $AGIO — A Hematology Biotech With $52-55 Analyst Targets $SHLS — Solar EBOS Maker Near $7, Guidance Raised https://truthsandnews.com/markets/10-stocks-to-watch-tomorrow-sept-4-2026-small-cap-movers

0 · Reply

Merlintrader Sep. 2 at 1:01 AM

Agios Pharmaceuticals ($AGIO) Stock Hub 2026: Can the Mitapivat Launch Carry the November 1 Sickle Cell Decision? Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/agios-pharmaceuticals-stock-hub/

0 · Reply

stu4 Aug. 30 at 6:36 PM

$AGIO Never said better !! @lnoa

0 · Reply

stu4 Aug. 30 at 6:29 PM

$AGIO the CEO’s have been a parade of failures Fouse…she ruined Bunge …goof Goff , he was a mere middle man at Alexion and let go No super scientists here for 7 years . Snowden laid the golden goose egg for these hacks to suck down a salary on ! He went with his brain to another start up in Mass. @Bornjever …

0 · Reply

Stonky_Mcprofitface Aug. 27 at 10:57 PM

$AGIO Stu - put on your CPAP machine and shut up.

1 · Reply

Bornjever Aug. 24 at 2:40 PM

$AGIO so I do know this company has a sickle cell therapy that is in pill form and for years I lost money in therapy that was infused into folks but was not very effective and supposedly this therapy works and has limited side effects . So what else am I missing ??

0 · Reply

Agios Pharmaceuticals price target raised to $52 from $46 at Citi

2026-07-30T16:40:20.000Z - 6 weeks ago

Agios Pharmaceuticals price target raised to $55 from $52 at H.C. Wainwright

Jul 30, 2026, 11:36 AM EDT - 6 weeks ago

Agios Pharmaceuticals Transcript: Transcript

Jul 30, 2026, 9:57 AM EDT - 6 weeks ago

Agios Pharmaceuticals Quarterly report

Jul 30, 2026, 7:12 AM EDT - 6 weeks ago

Agios Pharmaceuticals Slides

2026-07-30T11:10:47.000Z - 6 weeks ago

Agios Pharmaceuticals reports Q2 EPS ($1.69), consensus ($1.66)

Jul 30, 2026, 6:32 AM EDT - 6 weeks ago

Agios Pharmaceuticals Earnings release

Jul 30, 2026, 6:30 AM EDT - 6 weeks ago

Agios Reports Second Quarter 2026 Financial Results and Provides Business Update

2026-07-21T15:05:37.000Z - 7 weeks ago

Agios Pharmaceuticals price target lowered to $52 from $54 at H.C. Wainwright

2026-07-21T12:20:27.000Z - 7 weeks ago

Agios Pharmaceuticals down 13% at $34.75 on topline results from tebapivat trial

2026-07-21T11:21:10.000Z - 7 weeks ago

Agios Pharmaceuticals announces topline results from tebapivat trial

Jul 21, 2026, 7:07 AM EDT - 7 weeks ago

Agios Pharma to discontinue sickle cell disease treatment development

Jul 21, 2026, 7:00 AM EDT - 7 weeks ago

Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

2026-07-07T16:05:37.000Z - 2 months ago

Agios Pharmaceuticals rises 13.5%

2026-07-07T15:40:11.000Z - 2 months ago

Leerink sees Priority Review designation as positive sign for Agios’ mitapivat

2026-07-07T15:25:11.000Z - 2 months ago

H.C. Wainwright sees FDA Priority Review as positive signal for Agios’ mitapivat

2026-07-07T14:06:03.000Z - 2 months ago

Agios Pharmaceuticals rises 12.9%

2026-07-07T13:20:27.000Z - 2 months ago

Agios Pharmaceuticals price target raised to $46 from $40 at BofA

2026-07-07T13:15:43.000Z - 2 months ago

Agios Pharmaceuticals price target raised to $41 from $36 at Truist

2026-07-07T11:31:01.000Z - 2 months ago

Agios Pharmaceuticals price target raised to $32 from $28 at RBC Capital

2026-07-07T11:16:10.000Z - 2 months ago

Agios Pharmaceuticals granted priority review for mitapivat sNDA

Jul 7, 2026, 7:00 AM EDT - 2 months ago

U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease

Jun 29, 2026, 7:00 AM EDT - 2 months ago

Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET

2026-06-15T10:06:50.000Z - 3 months ago

Agios Pharmaceuticals price target raised to $54 from $50 at H.C. Wainwright

2026-06-14T20:35:05.000Z - 3 months ago

Agios Pharmaceuticals presented results from Phase 3 trial of mitapivat

Jun 13, 2026, 9:00 AM EDT - 3 months ago

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Jun 13, 2026, 9:00 AM EDT - 3 months ago

Agios Pharmaceuticals Transcript: EHA 2026

Jun 13, 2026, 9:00 AM EDT - 3 months ago

Agios Pharmaceuticals Slides: FY 2026

2026-06-10T23:45:10.000Z - 3 months ago

Agios Pharmaceuticals price target lowered to $31 from $36 at JPMorgan

Jun 1, 2026, 8:00 AM EDT - 3 months ago

Agios Pharmaceuticals Transcript: Status update

Jun 1, 2026, 8:00 AM EDT - 3 months ago

Agios Pharmaceuticals Slides: Status update

Jun 1, 2026, 8:00 AM EDT - 3 months ago

Agios Pharmaceuticals Press release: Status update

2026-06-01T09:13:35.000Z - 3 months ago

Agios Pharmaceuticals enters license pact with Oscotec to develop cevidoplenib

Jun 1, 2026, 5:00 AM EDT - 3 months ago

Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

2026-05-29T15:28:43.000Z - 3 months ago

Agios Pharmaceuticals price target lowered to $40 from $41 at BofA

May 29, 2026, 7:21 AM EDT - 3 months ago

Agios scraps blood cancer drug program after study miss

May 29, 2026, 7:00 AM EDT - 3 months ago

Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes

May 22, 2026, 10:18 AM EDT - 3 months ago

Avanzanite Bioscience's Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia

May 22, 2026, 9:15 AM EDT - 3 months ago

Agios' PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia

May 19, 2026, 11:00 AM EDT - 3 months ago

Agios Pharmaceuticals Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 12, 2026, 9:31 AM EDT - 4 months ago

Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease

May 12, 2026, 9:30 AM EDT - 4 months ago

Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Agios Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Agios Pharmaceuticals Earnings release: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Agios Pharmaceuticals Slides: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Agios Pharmaceuticals Quarterly report: Q1 2026

Apr 29, 2026, 6:30 AM EDT - 4 months ago

Agios Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Agios Pharmaceuticals Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Agios Pharmaceuticals Proxy statement: Proxy filing

Apr 6, 2026, 7:00 AM EDT - 5 months ago

Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

Mar 31, 2026, 8:45 AM EDT - 5 months ago

PK Activation Gains Momentum in Thalassemia Agios' Aqvesme Launch Reflects Strong Promise with Deliberate Uptake

Mar 31, 2026, 7:00 AM EDT - 5 months ago

Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA

Mar 2, 2026, 11:50 AM EST - 6 months ago